Next Article in Journal
Mapping of Absolute Host Concentration and Exchange Kinetics of Xenon Hyper-CEST MRI Agents
Next Article in Special Issue
3-Hydroxypropane-1,2-Diyl Dipalmitoleate—A Natural Compound with Dual Roles (CB1 Agonist/FAAH1 Blocker) in Inhibiting Ovarian Cancer Cell Line
Previous Article in Journal
Peripheral Mechanisms of Neuropathic Pain—The Role of Neuronal and Non-Neuronal Interactions and Their Implications for Topical Treatment of Neuropathic Pain
Previous Article in Special Issue
Comparison of Five Oral Cannabidiol Preparations in Adult Humans: Pharmacokinetics, Body Composition, and Heart Rate Variability
Due to scheduled maintenance work on our core network, there may be short service disruptions on this website between 16:00 and 16:30 CEST on September 25th.
Review

Clinical Evidence of Magistral Preparations Based on Medicinal Cannabis

1
Evidence-Based Therapeutics Group, Clinical Pharmacology, Universidad de La Sabana, Chía 140013, Colombia
2
Pain and Palliative Group, Universidad de La Sabana, Chía 140013, Colombia
*
Author to whom correspondence should be addressed.
Academic Editors: Maurizio Bifulco and Simona Pisanti
Pharmaceuticals 2021, 14(2), 78; https://0-doi-org.brum.beds.ac.uk/10.3390/ph14020078
Received: 23 December 2020 / Revised: 12 January 2021 / Accepted: 18 January 2021 / Published: 21 January 2021
Cannabis has been widely used as a medicinal plant for millennia; however, studies related to its main components were first conducted in 1960. Subsequently, laboratories have produced new components and structures related to its active biological properties. Countries that have approved the medicinal use of cannabis impose regulations that govern its clinical and scientific use. One means of administering medicinal cannabis is via a magistral preparation that must have a medical prescription and be prepared in an establishment that meets quality standards to ensure the quantities of its main components, such as tetrahydrocannabinol (THC) and cannabidiol (CBD). Furthermore, suppliers must have a clear indication of its use in the patient before prescription. This review shows the published evidence regarding the clinical use of medicinal cannabis magistral preparations in the management of post-chemotherapy nausea and vomiting, neuropathic pain in multiple sclerosis, and anorexia and cachexia in patients with HIV. View Full-Text
Keywords: magistral preparation; medicinal cannabis; anorexia; cachexia in HIV; post-chemotherapy nausea and vomiting; neuropathic pain in multiple sclerosis; pharmacology magistral preparation; medicinal cannabis; anorexia; cachexia in HIV; post-chemotherapy nausea and vomiting; neuropathic pain in multiple sclerosis; pharmacology
Show Figures

Figure 1

MDPI and ACS Style

Arias, S.; Leon, M.; Jaimes, D.; Bustos, R.-H. Clinical Evidence of Magistral Preparations Based on Medicinal Cannabis. Pharmaceuticals 2021, 14, 78. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14020078

AMA Style

Arias S, Leon M, Jaimes D, Bustos R-H. Clinical Evidence of Magistral Preparations Based on Medicinal Cannabis. Pharmaceuticals. 2021; 14(2):78. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14020078

Chicago/Turabian Style

Arias, Sara, Marta Leon, Diego Jaimes, and Rosa-Helena Bustos. 2021. "Clinical Evidence of Magistral Preparations Based on Medicinal Cannabis" Pharmaceuticals 14, no. 2: 78. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14020078

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop